Patient-based outcome measures were significantly reduced at weeks 12 and 24 of brodalumab therapy compared with baseline scores. Patient-rated disease severity (A) Visual Analogue Scale scores, (B) mean DLQI scores, (C) mean Beck Depression Inventory scores, and (D) Mean PHQ-9 scores were reduced significantly at weeks 12 and 24. DLQI, Dermatology Life Quality Index; PHQ-9, Patient Health Questionnaire-9.